Aktienanalyse zu Ensysce Biosciences Inc (ENSC)ENSCEnsysce Biosciences Inc

Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical company. It develops solutions for severe pain relief while reducing the potential for opioid misuse, abuse, and overdose. Its pipeline includes an abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection (TAAP) platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant (MPAR) platform. Its lead product, PF614, is a TAAP extended-release oxycodone and a potential analgesic to treat severe pain. Its second product, PF614-MPAR, is to treat severe pain with the added benefit of oral overdose protection, is a combination product of the TAAP prodrug PF614 with a trypsin inhibitor. Additionally, nafamostat, which is an ingredient in its overdose protection combination products, is also being developed for the intended purpose of treating infection and pulmonary lung diseases. It is also developing novel neuroplastogenic therapies for complex regional pain syndrome. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Ensysce Biosciences Inc is not a good buy right now. The current price is $0.34, and the stock has experienced a significant decline of 64.09% year-to-date. Additionally, the RSI is at a very low 9.06, indicating extreme oversold conditions, which typically suggests a potential for a rebound but also reflects severe weakness in market sentiment. The main risk is the company's negative earnings trend, with an EPS of -0.20 expected for the next quarter, which could further pressure the stock price.